Under 75, any sex, with Myelofibrosis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Rate of Non-relapse Mortality at 100 Days Post-transplantPrimary· Non-relapse mortality at 100 days post-transplant
To evaluate the safety of Fludarabine/Busulfan as conditioned regimen for allogeneic stem cell transplantation in patients with myelofibrosis/myelodysplastic syndrome at 100 days post-transplant
Infections
Group
Value
95% CI
Participants With Myelofibrosis and Myelodysplastic Syndrome
1
Organ Failures
Group
Value
95% CI
Participants With Myelofibrosis and Myelodysplastic Syndrome
2
Sudden death: likely due to ischemic cardiac event
Group
Value
95% CI
Participants With Myelofibrosis and Myelodysplastic Syndrome
1
Efficacy of This Therapy 3 Years Post-transplantSecondary· Up to 3 years post-transplant
Efficacy Assessed as Number of Participants with Overall Survival, Leukemia Progression, Primary Graft Failure and Complete Hematological Response. Primary graft failure is defined as failure to achieve an ANC \>/= 0.5 x 10 (9)/L for 3 consecutive days and evidence of donor chimerism by Day +28. Complete hematological response is defined by hemoglobin \>/= 120 g/L; or achievement of transfusion independence, with stable Hb \> 110 g/L, for RBC transfusion-dependent participants; Spleen not palpable; platelet count 150 x 10 (9)/L; White blood cell 4 x 10 (9)/L to 10 x 10(9)/L.
Overall survival at 3 years
Group
Value
95% CI
Participants With Myelofibrosis and Myelodysplastic Syndrome
25
Leukemia progression
Group
Value
95% CI
Participants With Myelofibrosis and Myelodysplastic Syndrome
27
Primary graft failures
Group
Value
95% CI
Participants With Myelofibrosis and Myelodysplastic Syndrome
0
Complete hematological remission
Group
Value
95% CI
Participants With Myelofibrosis and Myelodysplastic Syndrome
44
Adverse events — posted to ClinicalTrials.gov
Time frame: January 2006 to May 2012.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Participants With Myelofibrosis and Myelodysplastic Syndrome
The goal of this clinical research study is to learn if using a combination of fludarabine, busulfan, and antithymocyte globulin (ATG) can help to control myelofibrosis or myelodysplastic syndrome in patients receiving a bone marrow or blood stem cell transplant. The safety of these drugs will also be studied.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06954987 — Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell
· Phase 2
· not yet recruiting
NCT06996119 — Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu
· Phase 1
· not yet recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer
· Phase 2
· recruiting
NCT07524530 — Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
· Phase 2
· not yet recruiting
NCT07228624 — Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas
· Phase 2
· recruiting
Other recruiting trials for Myelofibrosis
Currently open trials in the same condition.
NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa
· Phase 1
· recruiting
NCT06781099 — Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
· NA
· recruiting
NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
· recruiting
NCT07342712 — Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation Levels
· active not recruiting
NCT06533813 — Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
· recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem
· Phase 1, PHASE2
· not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and
· Phase 1
· not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che
· Phase 2
· not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca
· Phase 2
· not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar
· Phase 1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 21 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00475020.